Tuesday, September 22, 2020

NEWSPAPER PUBLISHED WEEKLY ON WEDNESDAY • WEBSITE UPDATED WEEKLY FOR THURSDAY

Home Opinions Thinking about health: Ballot measure would let California negotiate drug prices

Thinking about health: Ballot measure would let California negotiate drug prices

By Trudy Lieberman | Rural Health News Service

The fight in California over a ballot initiative that would begin to control the price of pharmaceuticals paid by state programs shows how difficult it is to “do something” about the high price of prescription drugs.

According to the Bureau of Labor Statistics, U.S. drug spending rose 7 percent this year – the biggest increase in 24 years – and most Americans now think drug prices are unreasonable. So it’s not surprising the pharmaceutical industry is running scared and, with its deep pockets, is spending big to convince millions of Californians to vote “No” on Prop 61, a Nov. 8 ballot measure that would “do something.”

It’s a simple measure, says Roger Salazar, the spokesperson for the group “Yes On Prop 61.”  It would require the state to pay no more for prescription drugs than the U.S. Department of Veterans Affairs spends for the same medications.  The VA negotiates prices with pharmaceutical companies, and federal law requires that the department get a discount of at least 24 percent off the drugs it buys.   

That may seem reasonable considering the state spends billions on drugs it buys through such programs as CalPERS, the state employees retirement fund, the fee-for-service recipients in Medi-Cal, the state’s version of Medicaid, the state prison system, and an AIDS drug assistance program. Over time proponents say the measure could save the state billions.  For CalPERS alone they argue the measure could save almost $4 billion over 10 years. The state legislative office says the financial impact is “unknown.”

If proponent’s estimate of potential savings is correct, that’s hardly chump change. CalPERS, one of the country’s largest healthcare purchasers, saw its costs for specialty drugs – high-cost medicines for complex, chronic conditions – jump 30 percent in 2015.

The pharmaceutical industry, though, worries that if the measure passes in California, it could open the door for other states to follow. Even worse, it might lead to the federal government negotiating prices with drug companies as most other nations do.  “It’s a fairly straightforward expansion of price controls,” is how Stephen Ubl, president of the drug makers trade group, described it last summer in an interview with the New York Times.

The drug industry has fought against such negotiations for decades. Recall that Medicare is prohibited by law from negotiating prices for the prescription drugs it pays for on behalf of 56 million beneficiaries. “We can’t negotiate for purchasing in one of the largest insurance systems in the world,” says former Medicare administrator Don Berwick.

The fight in California reveals one of the biggest political and powerful obstacles of all – money. Two weeks before the election, the drug industry had poured $109 million into its campaign to defeat the measure, a sum that makes it the most expensive campaign for or against a single ballot initiative in the state’s history, according to Salazar’s group,

High on the list of companies giving money to defeat the measure are household names like Johnson & Johnson, Merck, and Pfizer, which each tossed in more than $9 million.

Their arguments have a familiar ring, similar to ones the drug industry has used before when price controls edged too close to their bottom lines. They argue that government interference with prices could lead to higher drug costs, treatment delays and even denial of coverage. They say the proposal offers little guidance for implementation.

Their tactics are familiar too. They’ve enlisted the help of several patient advocacy groups to support their position – groups like the California Hepatitis C Task Force and the Lupus Foundation of Southern California, which have received recent drug industry contributions.

When Los Angeles Times business columnist David Lazarus asked Kathy Fairbanks, the spokeswoman for the “No Prop 61” campaign,” if she’d characterize high drug prices as a problem for patients, she said no, that’s not how she would put it. “It’s an issue, how about that?” She added healthcare costs are top of mind for a lot of people, but “Proposition 61 isn’t the answer.”

It’s fair to ask:  Then what is it?  Two other weaker attempts in California to “do something” about drug prices failed this year. One was a measure to require insurers to give detailed information about drug costs and drug makers to give notice of future price increases. The other would have required more transparency about research and development, production and marketing costs for drugs with a wholesale price of more than $10,000 a year.    

The battle is being fought on the airwaves, and voters are confused.

Money talks!  The question remains: When will the needs of the public and the health system in general talk louder?

What do you think should be done to control drug prices? Write to Trudy at trudy.lieberman@gmail.com.

Submissions
Submissions
The Williams Pioneer Review has a small staff of one, covering all of Colusa County; but we’re proud to have the assistance of a large army of community contributors to extend our range and reach. This is one of those stories. If you have a story you would like to share, please email them to: news@colusacountynews.com or give us a call.

More News

Three killed on I-5 in two separate accidents 

Three people were killed on Interstate 5 in Colusa County over a five day period in two separate accidents.  A Yuba City couple were killed...

Garden Club Plant Sale

The Garden Club of Colusa County hosted their fall plant sale in the Davison Pavilion in Colusa on Saturday, Sept. 8. The event, which...

Coaches Corner: Dan Kiely

Soccer in Colusa County has a long history of competitive play and a major contributor to that tradition is Colusa High School boys’ soccer...

First Patriot Day ceremony held at Williams Elementary School

Students who attend Williams Elementary School were not alive 19 years ago when hijackers used airplanes as weapons of destruction to kill nearly 3,000...

Distance learning raises questions about home imagery

Editors Note: The article has been updated from the print version to correct the spelling of Tiffany Sines. Distance learning seems to be more challenging...

Local Government

County appoints new Airport Advisory Committee

The Colusa County Board of Supervisors on Sept. 1 appointed seven members to the newly restructured Airport Advisory Committee. The previous committee of about 15...

Colusa Police Department: July 2020

The City of Colusa Police Department responded to 382 calls for service, up from 311 in June. There were an additional 31 calls to...

City of Colusa adopts strategy for economic development

The Colusa City Council last week adopted the final Comprehensive Economic Development Strategy, a report that will serve as a roadmap intended to diversify...

Public & Legal Notices

FICTITIOUS BUSINESS NAME STATEMENT FILE NO. 2020-0000072 Date filed: September 11, 2020 The following persons are doing business as: GULLATT RANCH Business Address: 6880 GREENBAY ROAD, ARBUCKLE, CA 95912 Mailing...

FICTITIOUS BUSINESS NAME STATEMENT FILE NO. 2020-0000071 Date filed: September 1, 2020 The following persons are doing business as: C & C ENGINEERING Business Address: 2081 LONE STAR ROAD,...

Notice of Lien Sale

NOTICE OF LIEN SALE SEPTEMBER 20, 2020 AT 5:00 PM 423 SIOC STREET, COLUSA, CA 95932 8’  3’ GOLD WING 09/16/2020 • WPR #2020-1142

CIUDAD DE COLUSA AVISO DE AUDIENCIA PÚBLICA

CIUDAD DE COLUSA AVISO DE AUDIENCIA PÚBLICA AVISO SE DA A LA PRESENTE QUE la Comisión de Ciudad de Colusa y  Planificación llevará a cabo un...

CITY OF COLUSA NOTICE OF PUBLIC HEARING

CITY OF COLUSA NOTICE OF PUBLIC HEARING NOTICE IS HEREBY GIVEN that the City of Colusa and Planning Commission will hold public workshop on Wednesday, September...